Aimed Bio said Friday it has received preliminary approval from the Korea Exchange for its Kosdaq listing.

This comes just two months after the preliminary review request in July. Aimed Bio plans to immediately submit its securities registration statement and commence the public offering process. Mirae Asset Securities is the lead underwriter.

Aimed Bio was established in 2018 as a spin-off from Samsung Medical Center and possesses an ADC (antibody-drug conjugate) development platform based on unmet clinical needs. Building on this, it is developing a pipeline that enhances clinical predictability and applicability.

The company is developing various ADC candidates. In January 2025, it licensed AMB302 to U.S.-based Biohaven. In May, it also signed a technology transfer option agreement for AMB303 with SK plasma, strengthening its position in both global and Korean markets.

Earlier, Aimed Bio demonstrated its technological prowess and business viability by receiving an A grade from two evaluation agencies in the technology assessment for its special listing. Furthermore, it successfully raised 51.1 billion won ($36.6 million) in a pre-IPO round this year, bringing its cumulative investment since its establishment to 113.5 billion won.

“This preliminary approval for Kosdaq listing reaffirms our technological maturity and growth potential,” Aimed Bio CEO Her Nam-gu said. “Through the listing, we will leap forward as a leading company expanding our influence beyond Korea into the global ADC market.”